Logo
Asia Pacific Injectable Drugs Market 2020-2030

Asia Pacific Injectable Drugs Market 2020-2030

Bonafide Trust 02-02-2022 109 Pages
Region : Asia-Pacific Category : Lifescience Healthcare

Asia Pacific injectable drugs market will grow by 13.0% annually with a total addressable market cap of $2,165.4 billion over 2021-2030 owing to the increasing prevalence of chronic diseases, rising use of self-administered injectable formulations, technological advancements in drug development, and growing approvals of new injectable drugs such as COVID-19 vaccines. Highlighted with 30 tables and 53 figures, this 109-page report “Asia Pacific Injectable Drugs Market 2020-2030 by Molecule Type (Small, Large), Drug Class (mAbs, Immunoglobulin, Insulin, Vaccines, Cytokines, Peptide Hormone, Blood Factors), Delivery (Pre-filled Syringe, Infusions, Others), Application (Oncology, Infectious Diseases, Autoimmune, Cardiovascular), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific injectable drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific injectable drugs market in every aspect of the classification from perspectives of Molecule Type, Drug Class, Delivery, Application, Distribution Channel, and Country. Based on Molecule Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Small Molecule • Large Molecule Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Monoclonal Antibodies (mAbs) • Immunoglobulin • Insulin • Vaccines • Cytokines • Peptide Hormone • Blood Factors • Other Drug Classes Based on Delivery, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Pre-filled Syringe • Infusions • Other Deliveries Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Oncology • Infectious Diseases • Autoimmune Diseases • Cardiovascular Diseases • Pain • Neurology • Other Applications Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospital Pharmacy • Retail Pharmacy • E-Commerce Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Molecule Type, Drug Class, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Amgen Inc. Baxter International Inc. Eli Lilly and Company Gilead Sciences Inc. GlaxoSmithKline PLC Johnson & Johnson Merck & Co. Inc. Moderna, Inc. Novartis AG Novo Nordisk AS Pfizer Inc. Sanofi SA Teva Pharmaceuticals Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Read More

Card image cap

Interested in this report?
Get your FREE sample!

Requirement Gathering & Methodology
Data Collection Techniques
Our Research Team & Data Sourcing
Data Science & Analytical Tools
Data Visualization & Presentation Skills
Project/ Report Delivery & After Sales Services